Pilot Prospective Evaluation of 99mTc-MDP Scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and Whole-Body MRI for Detection of Skeletal Metastases
- 1 July 2013
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Nuclear Medicine
- Vol. 38 (7), e290-e296
- https://doi.org/10.1097/rlu.0b013e3182815f64
Abstract
The aim of this study was to compare 99mTc-MDP bone scanning, 18F NaF PET/CT, 18F FDG PET/CT, and whole-body MRI (WBMRI) for detection of known osseous metastases. This prospective pilot trial (September 2007-April 2009) enrolled 10 participants (5 men, 5 women, 47-81 years old) diagnosed with cancer and known osseous metastases. 18F NaF PET/CT, 18F FDG PET/CT, and WBMRI were performed within 1 month for each participant. The image quality and evaluation of extent of disease were superior by 18F NaF PET/CT compared to 99mTc-MDP scintigraphy in all patients with skeletal lesions and compared to 18F FDG PET/CT in 3 of the patients with skeletal metastases. 18F NaF PET/CT showed osseous metastases where 18F FDG PET/CT was negative in another 3 participants. Extraskeletal metastases were identified by 18F FDG PET/CT in 6 participants. WBMRI with the combination of iterative decomposition of water and fat with echo asymmetry and least-squares estimation, short tau inversion recovery, and diffusion-weighted imaging pulse sequences showed fewer lesions than 18F NaF PET/CT in 5 patients, same number of lesions in 2 patients, and more lesions in 1 patient. WBMRI showed fewer lesions than 18F FDG in 3 patients and same lesions in 6 patients. Our pilot phase prospective trial demonstrated superior image quality and evaluation of skeletal disease extent with 18F NaF PET/CT compared to 99mTc-MDP scintigraphy and 18F FDG PET/CT, as well as the feasibility of multisequence WBMRI. In addition, 18F FDG PET/CT provided valuable soft-tissue information that can change disease management. Further evaluation of these findings using the recently introduced PET/MRI scanners is warranted.Keywords
This publication has 38 references indexed in Scilit:
- Hybrid 18F-FDG PET–MRI of the hand in rheumatoid arthritis: initial resultsClinical Rheumatology, 2011
- 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancersNuclear Medicine Communications, 2011
- 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)EJNMMI Research, 2011
- Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate CancerClinical Cancer Research, 2010
- SNM Practice Guideline for Sodium 18F-Fluoride PET/CT Bone Scans 1.0Journal of Nuclear Medicine, 2010
- Correlation Between Glycolytic Phenotype and Tumor Grade in Soft-Tissue Sarcomas by 18F-FDG PETJournal of Nuclear Medicine, 2010
- [F‐18]‐fluorodeoxy‐D‐glucose–positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adultsCancer, 2009
- Novel Strategy for a Cocktail 18F-Fluoride and 18F-FDG PET/CT Scan for Evaluation of Malignancy: Results of the Pilot-Phase StudyJournal of Nuclear Medicine, 2009
- Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaJournal of Clinical Oncology, 2007
- F-18 FDG PET/CT Evaluation of Osseous and Soft Tissue SarcomasClinical Nuclear Medicine, 2006